New treatment approach for liver cancer
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma
This study is testing a new treatment that combines two therapies to help fight advanced liver cancer, and if it works well, it could offer hope for patients looking for better options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10977330 on NIH RePORTER |
What this research studies
This research investigates a novel combination therapy targeting two oncogenes, AEG-1 and MDA-9, which are involved in the development and progression of hepatocellular carcinoma (HCC). The approach utilizes targeted nanoplexes to deliver AEG-1 siRNA and a specific small molecule inhibitor of MDA-9, aiming to reduce cancer cell invasion and improve treatment outcomes. By analyzing patient data and conducting experiments in human HCC xenografts, the research seeks to establish a more effective treatment for advanced liver cancer. Patients may benefit from this innovative therapy if it proves successful in clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with hepatocellular carcinoma, particularly those with advanced disease who have limited treatment options.
Not a fit: Patients with early-stage liver cancer or those whose cancer is not related to the oncogenes AEG-1 and MDA-9 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with advanced liver cancer.
How similar studies have performed: Other research has shown promising results with targeted therapies for cancer, suggesting potential success for this novel approach.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Sarkar, Devanand — Virginia Commonwealth University
- Study coordinator: Sarkar, Devanand
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.